Iqbal J. Hussain Sells 6,000 Shares of Centessa Pharmaceuticals (NASDAQ:CNTA) Stock

Key Points

• General Counsel Iqbal J. Hussain sold 6,000 shares of Centessa Pharmaceuticals at an average price of $17.23, reducing his ownership by 5.39% and retaining 105,386 shares valued at approximately $1.82 million.
• Centessa Pharmaceuticals' stock price increased by 2.3% during trading, reaching $18.05 with a notable trading volume of 1.28 million shares.
• Multiple analysts provided positive outlooks for the company's stock, with price targets ranging from $6.00 to $35.00, resulting in an average rating of "Moderate Buy".

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Get Free Report) General Counsel Iqbal J. Hussain sold 6,000 shares of Centessa Pharmaceuticals stock in a transaction on Friday, August 15th. The stock was sold at an average price of $17.23, for a total transaction of $103,380.00. Following the transaction, the general counsel directly owned 105,386 shares of the company's stock, valued at approximately $1,815,800.78. This trade represents a 5.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Centessa Pharmaceuticals Stock Performance

CNTA stock traded down $0.06 during midday trading on Wednesday, reaching $17.28. 771,190 shares of the company were exchanged, compared to its average volume of 1,179,671. The company has a debt-to-equity ratio of 0.32, a current ratio of 10.11 and a quick ratio of 10.12. The business has a 50-day moving average price of $15.08 and a two-hundred day moving average price of $14.52. Centessa Pharmaceuticals PLC Sponsored ADR has a one year low of $9.60 and a one year high of $19.09. The firm has a market capitalization of $2.31 billion, a price-to-earnings ratio of -9.65 and a beta of 1.48.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.38) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.03). Equities research analysts forecast that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Needham & Company LLC assumed coverage on shares of Centessa Pharmaceuticals in a research report on Wednesday, May 28th. They issued a "buy" rating and a $35.00 target price for the company. Truist Financial assumed coverage on shares of Centessa Pharmaceuticals in a research report on Monday, July 21st. They issued a "buy" rating and a $30.00 target price for the company. Oppenheimer assumed coverage on shares of Centessa Pharmaceuticals in a research report on Thursday, May 8th. They issued an "outperform" rating and a $6.00 target price for the company. Wall Street Zen cut shares of Centessa Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday. Finally, Chardan Capital reissued a "buy" rating and issued a $30.00 target price on shares of Centessa Pharmaceuticals in a research report on Tuesday, August 12th. Eleven research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $28.10.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. GF Fund Management CO. LTD. acquired a new position in Centessa Pharmaceuticals in the fourth quarter valued at about $31,000. Caitong International Asset Management Co. Ltd raised its stake in Centessa Pharmaceuticals by 15,209.5% in the first quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company's stock valued at $46,000 after purchasing an additional 3,194 shares in the last quarter. Osterweis Capital Management Inc. acquired a new position in Centessa Pharmaceuticals during the first quarter worth about $47,000. Barclays PLC raised its stake in Centessa Pharmaceuticals by 1,414.9% during the fourth quarter. Barclays PLC now owns 5,302 shares of the company's stock worth $89,000 after acquiring an additional 4,952 shares in the last quarter. Finally, BNP Paribas Financial Markets acquired a new position in Centessa Pharmaceuticals during the fourth quarter worth about $162,000. Institutional investors and hedge funds own 82.01% of the company's stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.